In the third quarter, Geneos Wealth Management Inc. cut its position in Northrop Grumman Corporation by 61.6%, disposing of 1,511 shares and retaining 943 shares valued at approximately $575,000 at quarter end. This reduction contrasts with several other institutions that either initiated small positions—Parvin Asset Management and Twin Peaks Wealth Advisors each invested roughly $25,000–$31,000 in the second quarter—or expanded stakes, such as NewSquare Capital which boosted its holding by 75% to 63 shares and City Holding Co., which more than doubled its stake to 100 shares. Hedge funds and other institutional investors collectively own 83.4% of the company, underscoring the prominence of strategic ownership shifts in driving market perception.

Director Mark A. Welsh III sold 97 shares on November 24 at an average of $564.08 per share for proceeds of $54,716, reducing his ownership by 2.22% to 4,281 shares valued at about $2.41 million. CEO Kathy J. Warden executed a larger divestiture on January 5, disposing of 7,000 shares at an average of $600.00 for total proceeds of $4.2 million, trimming her stake by 3.47% to 194,602 shares worth approximately $116.8 million. Over the past three months, insiders have sold a combined 10,097 shares for $6.1 million, though insiders still retain 0.23% of the outstanding stock.

For the quarter ended September, Northrop Grumman reported earnings per share of $7.67, surpassing consensus estimates by $1.24, while revenue reached $10.42 billion, falling short of the $10.68 billion analysts forecast but still marking 4.3% year-over-year growth. Return on equity stood at 25.49% and net margin at 9.82%. The company reaffirmed its full-year guidance of $25.65 to $26.05 in EPS for fiscal 2025, with the analyst community projecting $28.05 in earnings for the current fiscal year, reflecting confidence in continued margin stability despite revenue pressures in Defence Systems and Space segments.

Northrop Grumman declared a quarterly dividend of $2.31, translating to an annualized payout of $9.24 and a yield of approximately 1.5%, with a payout ratio of 33.24%. On the ratings front, two firms assign a Strong Buy, twelve maintain Buy recommendations and seven Hold, resulting in a consensus Moderate Buy rating and an average price target of $647.35. Recent upgrades from BNP Paribas and price-target increases by Morgan Stanley and UBS underscore expectations for upside from B-21 bomber production ramp and leadership in nuclear triad contracts, even as some analysts caution that valuation premiums relative to peers may limit near-term total return.